Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘ multiple sclerosis (MS) medication for relapsing forms of the disease, that could be injected at home. The new formulation is designed to be given under the skin, or subcutaneously, every two or three months, which could offer a […]
The post Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com